Id | Content |
---|---|
F1 | The options ("Option" and collectively, "Options") have been issued from the Company's 2022 Equity Incentive Plan, that was approved by the Members of the Board of Directors on August 1, 2023. |
F2 | The Options will vest and become exercisable with respect to 40% of the shares starting August 1, 2023, with one forty-eighth (1/48th) of the shares vesting each calendar month thereafter on the same day of the month as the first vesting date. The remaining 60% of the shares will vest and become exercisable once HeartBeam, Inc. receives FDA Clearance for marketing of HeartBeam's synthesized 12-Lead product obtained by signal synthesis from the recorded xyz signals. |